Strategic Acquisition Helios Global Group was recently acquired by Telemos Capital in October 2024, signaling private equity backing and potential rapid investment in growth initiatives, integration capabilities, and expanded service offerings that could open doors to joint ventures or expanded contracts.

Global Footprint With offices across the UK and an established US base in Guilford, CT, Helios Global Group demonstrates a multinational presence that enables cross-border collaborations, regional market access strategies, and opportunities to upsell global and regional medical affairs, publications, and market access services.

Full-Service Offering As a family of agencies delivering strategic consultancy, medical and scientific communications, commercialisation, and value evidence, Helios can position as a one-stop shop for pharma and biotech clients seeking end-to-end communications solutions, simplifying procurement and expanding deal sizes.

Financial Scale Estimated revenue of $10M–$25M and a 201–500 employee base indicate a mid-market profile with potential for scalable services, cross-sell across agencies (Helios, Selene, Apollo, Cogentia), and opportunities to pursue larger projects with mid-market and larger pharma clients.

Industry Focus Specializing in medical affairs, publications, commercial, and market access within pharma and biotech positions Helios as a partner for evidence generation, payer value analyses, and market access strategies in a landscape of evolving payer requirements and health economics needs.